Crescendo Bioscience to Present Data on the Use of Vectra™ DA in Assessing Response to Treatments at Crescendo Bioscience/Associate Rheumatology Health Professional Annual Meeting

Published: Nov 12, 2012

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2012 (GLOBE NEWSWIRE) -- Crescendo Bioscience®, a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other auto-immune diseases, announced today that it will present data from several studies that confirm Vectra™ DA's performance in measuring changes in disease activity in patients with RA following treatment with a number of therapies including traditional disease-modifying anti-rheumatic drugs (DMARDs) and biological therapies at the American College of Rheumatology/Associate Rheumatology Health Professional (ACR/ARHP) annual meeting, held in Washington, DC, November 11-14. The clinical data from these studies add to the growing body of evidence that Vectra DA can provide rheumatologists objective insight into the molecular disease activity of rheumatoid arthritis to potentially help them make better treatment decisions for their patients.

Back to news